(Q34156183)

31 July 2017

title

5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy (English)

1 reference

31 July 2017

Eric P M Prinssen

1

1 reference

31 July 2017

Francis C Colpaert

series ordinal

2

1 reference

31 July 2017

Wouter Koek

series ordinal

3

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

European Journal of Pharmacology

31 July 2017

published in

1 reference

31 July 2017

volume

453

1 reference

31 July 2017

issue

2-3

1 reference

31 July 2017

page(s)

217-221

1 reference

5-HT1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine.

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902430-5

Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902430-5

The putative <<silent>> 5-HT(1A) receptor antagonist, WAY 100635, has inverse agonist properties at cloned human 5-HT(1A) receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902430-5

5-HT1A receptor agonists: recent developments and controversial issues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902430-5

Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902430-5

8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902430-5

5-HT1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902430-5

Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902430-5

Agonist and inverse agonist efficacy at human recombinant serotonin 5-HT1A receptors as a function of receptor:G-protein stoichiometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902430-5

The cataleptogenic effects of the neuroleptic nemonapride are attenuated by its 5-HT1A receptor agonist properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902430-5

Interactions between neuroleptics and 5-HT(1A) ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902430-5

Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902430-5

Effects of WAY 100635 on antipsychotic-induced catalepsy in 5-HT depleted animals: a role for tonic activation of 5-HT(1A) receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902430-5

Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902430-5

10.1016/S0014-2999(02)02430-5

7 January 2021

Identifiers

DOI

1 reference

31 July 2017

1 reference